|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000010295 |
Summary for IFFO1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000010295 | Gene symbol | IFFO1 |
| Gene name | intermediate filament family orphan 1 | |
| HGNC | 24970 | |
| Entrez ID | 25900 | |
| Gene type | protein_coding | |
| Synonyms | IFFO1|HOM-TES-103 | |
| UniProtAcc | Q0D2I5 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for IFFO1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| IFFO1 | 5.31e+02 | -1.27e+00 | 1.64e-01 | -7.76e+00 | 8.43e-15 | 2.93e-14 | LUSC |
| IFFO1 | 3.72e+02 | -1.43e+00 | 3.90e-01 | -3.67e+00 | 2.41e-04 | 9.67e-04 | BLCA |
| IFFO1 | 5.28e+02 | -1.08e+00 | 4.11e-01 | -2.64e+00 | 8.28e-03 | 2.12e-02 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for IFFO1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for IFFO1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRP | cg01493517 | chr12:6556281 | CGI:chr12:6555259-6556135 | promoter | 2.88e-01 | 1.86e-01 | 4.01e+00 | 6.15e-05 | 5.03e-04 | 1.03e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg00983904 | chr12:6556122 | CGI:chr12:6555259-6556135 | promoter | 5.98e-01 | 1.91e-01 | 4.31e+00 | 1.67e-05 | 5.26e-04 | 4.06e-01 |
| LUSC | cg08875705 | chr12:6556164 | CGI:chr12:6555259-6556135 | promoter | 6.75e-01 | 3.45e-01 | 4.30e+00 | 1.70e-05 | 5.26e-04 | 3.30e-01 |
| LUSC | cg23737737 | chr12:6556204 | CGI:chr12:6555259-6556135 | promoter | 5.95e-01 | 2.66e-01 | 4.23e+00 | 2.39e-05 | 5.26e-04 | 3.29e-01 |
| LUSC | cg00082235 | chr12:6555370 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 4.66e-01 | 3.31e-01 | 3.52e+00 | 4.34e-04 | 1.52e-03 | 1.35e-01 |
| LUSC | cg00363813 | chr12:6555706 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 6.17e-01 | 4.62e-01 | 4.20e+00 | 2.65e-05 | 5.26e-04 | 1.55e-01 |
| LUSC | cg17198308 | chr12:6555942 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 6.02e-01 | 4.10e-01 | 4.25e+00 | 2.11e-05 | 5.26e-04 | 1.92e-01 |
| LUSC | cg01979888 | chr12:6556258 | CGI:chr12:6555259-6556135 | promoter | 6.65e-01 | 4.67e-01 | 3.98e+00 | 6.89e-05 | 6.07e-04 | 1.97e-01 |
| LUSC | cg01493517 | chr12:6556281 | CGI:chr12:6555259-6556135 | promoter | 6.22e-01 | 4.03e-01 | 3.81e+00 | 1.41e-04 | 8.14e-04 | 2.19e-01 |
| COAD | cg00983904 | chr12:6556122 | CGI:chr12:6555259-6556135 | promoter | 6.49e-01 | 5.47e-01 | 3.41e+00 | 6.49e-04 | 1.58e-03 | 1.03e-01 |
| COAD | cg08875705 | chr12:6556164 | CGI:chr12:6555259-6556135 | promoter | 7.44e-01 | 6.14e-01 | 4.18e+00 | 2.95e-05 | 1.34e-04 | 1.29e-01 |
| COAD | cg23737737 | chr12:6556204 | CGI:chr12:6555259-6556135 | promoter | 6.59e-01 | 5.11e-01 | 3.80e+00 | 1.47e-04 | 4.75e-04 | 1.48e-01 |
| COAD | cg00082235 | chr12:6555370 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 5.06e-01 | 3.61e-01 | 4.06e+00 | 4.85e-05 | 1.98e-04 | 1.45e-01 |
| COAD | cg01979888 | chr12:6556258 | CGI:chr12:6555259-6556135 | promoter | 7.10e-01 | 6.07e-01 | 3.80e+00 | 1.47e-04 | 4.75e-04 | 1.02e-01 |
| COAD | cg01493517 | chr12:6556281 | CGI:chr12:6555259-6556135 | promoter | 6.74e-01 | 5.23e-01 | 4.00e+00 | 6.44e-05 | 2.47e-04 | 1.51e-01 |
| BLCA | cg24853956 | chr12:6554516 | CGI:chr12:6555259-6556135 | promoter,gene body | 4.73e-01 | 3.63e-01 | 3.01e+00 | 2.63e-03 | 4.87e-03 | 1.10e-01 |
| LIHC | cg00363813 | chr12:6555706 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 9.18e-02 | 2.38e-01 | -6.21e+00 | 5.16e-10 | 7.94e-09 | -1.46e-01 |
| LIHC | cg17198308 | chr12:6555942 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 7.52e-02 | 1.93e-01 | -5.20e+00 | 1.94e-07 | 9.20e-07 | -1.17e-01 |
| LIHC | cg01493517 | chr12:6556281 | CGI:chr12:6555259-6556135 | promoter | 1.51e-01 | 2.56e-01 | -5.30e+00 | 1.16e-07 | 5.95e-07 | -1.05e-01 |
| CHOL | cg24853956 | chr12:6554516 | CGI:chr12:6555259-6556135 | promoter,gene body | 5.49e-01 | 4.29e-01 | 2.58e+00 | 9.87e-03 | 2.15e-02 | 1.20e-01 |
| CHOL | cg00983904 | chr12:6556122 | CGI:chr12:6555259-6556135 | promoter | 4.89e-01 | 1.27e-01 | 2.36e+00 | 1.83e-02 | 2.92e-02 | 3.61e-01 |
| CHOL | cg08875705 | chr12:6556164 | CGI:chr12:6555259-6556135 | promoter | 5.33e-01 | 1.52e-01 | 2.36e+00 | 1.83e-02 | 2.92e-02 | 3.81e-01 |
| CHOL | cg23737737 | chr12:6556204 | CGI:chr12:6555259-6556135 | promoter | 5.03e-01 | 8.11e-02 | 2.51e+00 | 1.22e-02 | 2.39e-02 | 4.22e-01 |
| CHOL | cg00082235 | chr12:6555370 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 4.56e-01 | 2.21e-01 | 2.73e+00 | 6.38e-03 | 1.82e-02 | 2.35e-01 |
| CHOL | cg00363813 | chr12:6555706 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 5.72e-01 | 3.27e-01 | 2.43e+00 | 1.50e-02 | 2.65e-02 | 2.45e-01 |
| CHOL | cg17198308 | chr12:6555942 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 5.01e-01 | 2.67e-01 | 2.43e+00 | 1.50e-02 | 2.65e-02 | 2.34e-01 |
| CHOL | cg01979888 | chr12:6556258 | CGI:chr12:6555259-6556135 | promoter | 6.21e-01 | 2.26e-01 | 2.80e+00 | 5.09e-03 | 1.63e-02 | 3.95e-01 |
| CHOL | cg01493517 | chr12:6556281 | CGI:chr12:6555259-6556135 | promoter | 5.97e-01 | 2.47e-01 | 3.02e+00 | 2.51e-03 | 1.19e-02 | 3.50e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg24853956 | chr12:6554516 | CGI:chr12:6555259-6556135 | promoter,gene body | 4.65e-01 | 2.64e-01 | 1.42e+01 | 4.68e-46 | 3.39e-43 | 2.01e-01 |
| BRCA | cg00983904 | chr12:6556122 | CGI:chr12:6555259-6556135 | promoter | 6.24e-01 | 3.41e-01 | 1.24e+01 | 2.99e-35 | 9.18e-34 | 2.84e-01 |
| BRCA | cg08875705 | chr12:6556164 | CGI:chr12:6555259-6556135 | promoter | 6.96e-01 | 4.00e-01 | 1.22e+01 | 1.87e-34 | 5.01e-33 | 2.96e-01 |
| BRCA | cg23737737 | chr12:6556204 | CGI:chr12:6555259-6556135 | promoter | 6.26e-01 | 3.17e-01 | 1.22e+01 | 2.35e-34 | 6.23e-33 | 3.10e-01 |
| BRCA | cg00082235 | chr12:6555370 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 4.84e-01 | 3.03e-01 | 1.02e+01 | 3.17e-24 | 2.51e-23 | 1.81e-01 |
| BRCA | cg00363813 | chr12:6555706 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 6.29e-01 | 4.60e-01 | 9.38e+00 | 6.38e-21 | 3.73e-20 | 1.69e-01 |
| BRCA | cg17198308 | chr12:6555942 | CGI:chr12:6555259-6556135 | promoter,gene body,CDS,UTR,exon | 6.33e-01 | 4.42e-01 | 1.12e+01 | 2.38e-29 | 3.21e-28 | 1.91e-01 |
| BRCA | cg01979888 | chr12:6556258 | CGI:chr12:6555259-6556135 | promoter | 6.85e-01 | 4.37e-01 | 1.20e+01 | 2.72e-33 | 6.14e-32 | 2.48e-01 |
| BRCA | cg01493517 | chr12:6556281 | CGI:chr12:6555259-6556135 | promoter | 6.35e-01 | 3.94e-01 | 1.16e+01 | 6.57e-31 | 1.07e-29 | 2.42e-01 |
| KIRC | cg06237647 | chr12:6557373 | CGI:chr12:6555259-6556135 | promoter | 8.04e-01 | 9.30e-01 | -3.12e+00 | 1.79e-03 | 6.05e-03 | -1.25e-01 |
| LUAD | cg24853956 | chr12:6554516 | CGI:chr12:6555259-6556135 | promoter,gene body | 5.24e-01 | 4.06e-01 | 4.11e+00 | 3.97e-05 | 6.55e-04 | 1.18e-01 |
Top |
Exon skipping events with PSI in TCGA for IFFO1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| KIRP | exon_skip_89520 | 2.08e-01 | 8.49e-02 | 3.63e+00 | 2.88e-04 | 1.50e-03 | 1.23e-01 |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for IFFO1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for IFFO1 |
| TFs related to IFFO1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| IFFO1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for IFFO1 |
| RBPs related to ES in IFFO1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| PCPG | SNRPA | exon_skip_89520 | 7.00e+00 | 7.59e-03 | 7.34e+00 | 9.81e-01 | Female-biased |
| IFFO1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000010295 | AL450326.1,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000010295 | AL031595.2,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000010295 | TTTY10,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-LUSC |
| ENSG00000010295 | AC010889.1,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-LUSC |
| ENSG00000010295 | SGMS1-AS1,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-LUSC |
| ENSG00000010295 | IL6R-AS1,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-LUSC |
| ENSG00000010295 | SNHG14,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-LUSC |
| ENSG00000010295 | AL031595.2,hsa-mir-372,IFFO1 | Male-specific ceRNA | TCGA-LUSC |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs58141523 | chr12:13531856:G:C | - | 0.117674633326886 | 0.0305182658061865 | COAD | Female-baised eQTL |
| rs11611333 | chr12:10314468:A:G | - | 0.0661105416777465 | 0.0492879376108439 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs111227679 | chr12:3952300:A:G | - | 0.124187313608068 | 0.0060655519829771 | LGG | Male-baised eQTL |
| rs111977417 | chr12:3952375:C:T | - | 0.124187313608068 | 0.0060655519829771 | LGG | Male-baised eQTL |
| rs7978351 | chr12:3951793:T:C | - | 0.0995992310681459 | 0.0323292258303583 | LGG | Male-baised eQTL |
| rs35808522 | chr12:4879194:C:T | - | 0.070365529457062 | 0.043039653550177 | BLCA | Male-baised eQTL |
| rs12301837 | chr12:3435724:C:G | - | 0.0643024165780127 | 0.0328466175448527 | LUAD | Male-baised eQTL |
| rs61916001 | chr12:9019580:T:C | - | 0.0759616594276079 | 0.0331512067304252 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000010295 |
| CpG Site: cg13298466 | |
| Position to Gene: gene,exon | |
| Male Effect: -0.449609777639258 | |
| Female Effect: - | |
 | Gene ID: ENSG00000010295 |
| CpG Site: cg21440776 | |
| Position to Gene: gene,exon | |
| Male Effect: -0.449609777639258 | |
| Female Effect: - | |
 | Gene ID: ENSG00000010295 |
| CpG Site: cg17281677 | |
| Position to Gene: gene | |
| Male Effect: -0.449609777639258 | |
| Female Effect: - | |
 | Gene ID: ENSG00000010295 |
| CpG Site: cg13298466 | |
| Position to Gene: gene,exon | |
| Male Effect: -0.410529993670678 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg13298466 | chr12:6548998 | gene,exon | -0.449609777639258 | 9.73278219976835e-19 | -0.5866511034151034 | 5.169401765880527e-22 | LUAD |
| cg21440776 | chr12:6549212 | gene,exon | -0.449609777639258 | 9.73278219976835e-19 | -0.5866511034151034 | 5.169401765880527e-22 | LUAD |
| cg17281677 | chr12:6549391 | gene | -0.449609777639258 | 9.73278219976835e-19 | -0.5866511034151034 | 5.169401765880527e-22 | LUAD |
| cg13298466 | chr12:6548998 | gene,exon | -0.410529993670678 | 4.81256718494955e-09 | -0.41252310766746886 | 8.147141362660379e-12 | LIHC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of IFFO1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
